株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ファーマコビジランスの世界市場:治験段階、サービス業者、種類、最終用途、セグメント別の分析と予測

Pharmacovigilance Market Size, Share & Trends Analysis Report By Clinical Trial Phase (Pre-Clinical, Phase I, II, III, IV), By Service Provider (In-House, Contract Outsourcing), By Type, By End Use, And Segment Forecasts, 2019 - 2026

発行 Grand View Research, Inc. 商品コード 544763
出版日 ページ情報 英文 170 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.53円で換算しております。
Back to Top
ファーマコビジランスの世界市場:治験段階、サービス業者、種類、最終用途、セグメント別の分析と予測 Pharmacovigilance Market Size, Share & Trends Analysis Report By Clinical Trial Phase (Pre-Clinical, Phase I, II, III, IV), By Service Provider (In-House, Contract Outsourcing), By Type, By End Use, And Segment Forecasts, 2019 - 2026
出版日: 2019年04月12日 ページ情報: 英文 170 Pages
概要

当レポートでは、世界のファーマコビジランス (PV:医薬品安全性監視) 市場について分析し、技術の特性や市場の基本的構造、主な市場促進・抑制要因、全体的な市場規模の動向見通し (過去3年間・今後9年間分)、治験段階・サービス業者・治療手段・最終用途別、および地域別の詳細動向、市場競争環境 (市場シェア・求心力ほか)、主要企業のプロファイル・業績などを調査しております。

第1章 分析手法

第2章 エグゼクティブ・サマリー

第3章 ファーマコビジランス市場:市場データ・傾向・展望

  • 市場の内訳と範囲
  • 市場促進要因の分析
  • 市場抑制要因の分析
  • 市場浸透度・成長率の見通し
  • SWOT分析
  • 産業分野:ポーターのファイブフォース・モデル

第4章 ファーマコビジランス市場:治験段階別の予測値と動向分析

  • 治験段階別の動向分析
  • 前臨床
  • 第I相
  • 第II相
  • 第III相
  • 第VI相

第5章 ファーマコビジランス市場:サービス業者別の予測値と動向分析

  • サービス業者 (サービスプロバイダー) 別の動向分析
  • 内製型企業
  • 外注型企業

第6章 ファーマコビジランス市場:治療手段別の予測値と動向分析

  • 手段別の動向分析
  • 自発報告
  • 強化型ADR (医薬品有害反応) 報告
  • 標的特定型自発報告
  • コホート・イベントモニタリング
  • 電子カルテ (EHR) マイニング

第7章 ファーマコビジランス市場:最終用途別の予測値と動向分析

  • 最終用途 (エンドユース) 別の市場動向の分析
  • 病院
  • 研究機関
  • 各種産業

第8章 ファーマコビジランス市場:地域別の予測値と動向分析

  • 地域別の市場シェア (最新値、予測値)
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競争環境

  • 企業戦略のフレームワーク
  • 市場参入企業
  • 企業プロファイル
図表

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of key emerging companies
  • TABLE 3 North America Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 4 North America Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 5 North America Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 6 North America Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 7 U.S. Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 8 U.S. Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 9 U.S. Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 10 U.S. Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 11 Canada Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 12 Canada Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 13 Canada Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 14 Canada Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 15 Europe Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 16 Europe Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 17 Europe Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 18 Europe Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 19 U.K. Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 20 U.K. Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 21 U.K. Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 22 U.K. Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 23 Germany Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 24 Germany Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 25 Germany Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 26 France Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 27 France Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 28 France Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 29 France Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 30 Italy Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 31 Italy Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 32 Italy Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 33 Italy Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 34 Russia Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 35 Russia Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 36 Russia Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 37 Russia Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 38 Asia Pacific Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 39 Asia Pacific Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 40 Asia Pacific Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 41 Asia Pacific Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 42 Japan Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 43 Japan Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 44 Japan Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 45 Japan Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 46 China Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 47 China Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 48 China Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 49 China Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 50 India Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 51 India Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 52 India Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 53 India Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 54 Latin America Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 55 Latin America Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 56 Latin America Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 57 Latin America Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 58 Brazil Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 59 Brazil Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 60 Brazil Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 61 Brazil Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 62 Mexico Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 63 Mexico Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 64 Mexico Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 65 Mexico Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 66 MEA Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 67 MEA Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 68 MEA Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 69 MEA Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 70 South Africa Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 71 South Africa Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 72 South Africa Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 73 South Africa Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)
  • TABLE 74 Saudi Arabia Pharmacovigilance market estimates and forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 75 Saudi Arabia Pharmacovigilance market estimates and forecasts, by service provider, 2014 - 2025 (USD Million)
  • TABLE 76 Saudi Arabia Pharmacovigilance market estimates and forecasts, by type, 2014 - 2025 (USD Million)
  • TABLE 77 Saudi Arabia Pharmacovigilance market estimates and forecasts, by end use, 2014 - 2025 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Primary interviews in North America
  • Fig. 6 Primary interviews in Europe
  • Fig. 7 Primary interviews in Asia Pacific
  • Fig. 8 Primary interviews in Middle East and Africa
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Commodity flow analysis
  • Fig. 14 Pharmacovigilance market snapshot
  • Fig. 15 Penetration & growth prospect mapping
  • Fig. 16 Technology impact analysis
  • Fig. 17 Pharmacovigilance market dynamics
  • Fig. 18 Pharmacovigilance market driver impact
  • Fig. 19 Pharmacovigilance market restraint impact
  • Fig. 20 Strategy mapping
  • Fig. 21 Market participant categorization
  • Fig. 22 Company market position analysis
  • Fig. 23 Market differentiators
  • Fig. 24 Company market share analysis
  • Fig. 25 Competitive dashboard analysis
  • Fig. 26 Pharmacovigilance market: Product movement analysis
  • Fig. 27 Pharmacovigilance market product dashboard
  • Fig. 28 Global Preclinical market, 2014 - 2026 (USD Million)
  • Fig. 29 Global Phase I market, 2014 - 2026 (USD Million)
  • Fig. 30 Global Phase II market, 2014 - 2026 (USD Million)
  • Fig. 31 Global Phase III market, 2014 - 2026 (USD Million)
  • Fig. 32 Global Phase IV market, 2014 - 2026 (USD Million)
  • Fig. 33 Pharmacovigilance market: Service provider movement analysis
  • Fig. 34 Pharmacovigilance Service provider dashboard
  • Fig. 35 Global In house market, 2014 - 2026 (USD Million)
  • Fig. 36 Global Contract outsourcing market, 2014 - 2026 (USD Million)
  • Fig. 37 Pharmacovigilance market: Type movement analysis
  • Fig. 38 Pharmacovigilance Type dashboard
  • Fig. 39 Global Spontaneous Reporting market, 2014 - 2026 (USD Million)
  • Fig. 40 Global Intensified ADR Reporting market, 2014 - 2026 (USD Million)
  • Fig. 41 Global Targeted spontaneous reporting market, 2014 - 2026 (USD Million)
  • Fig. 42 Global Cohort Event Monitoring (CEM) market, 2014 - 2026 (USD Million)
  • Fig. 43 Global EHR Mining market, 2014 - 2026 (USD Million)
  • Fig. 44 Pharmacovigilance market: End Use movement analysis
  • Fig. 45 Pharmacovigilance End Use dashboard
  • Fig. 46 Global Hospitals market, 2014 - 2026 (USD Million)
  • Fig. 47 Global Research organizations market, 2014 - 2026 (USD Million)
  • Fig. 48 Regional market place: Key takeaways
  • Fig. 49 North America Pharmacovigilance market share by countries, 2018
  • Fig. 50 Europe Pharmacovigilance market share by countries, 2018
  • Fig. 51 Asia Pacific Pharmacovigilance market share by countries, 2018
  • Fig. 52 Latin America Pharmacovigilance market share by countries, 2018
  • Fig. 53 MEA Pharmacovigilance market share by countries, 2018
  • Fig. 54 Regional outlook, 2018 & 2026
  • Fig. 55 North America Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 56 U.S. Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 57 Canada Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 58 Europe Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 59 U.K. Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 60 Germany Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 61 France Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 62 Italy Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 63 Russia Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 64 Asia Pacific Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 65 Japan Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 66 China Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 67 India Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 68 Latin America Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 69 Mexico Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 70 Brazil Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 71 MEA Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 72 South Africa Pharmacovigilance market, 2014 - 2026 (USD Million)
  • Fig. 73 Saudi Arabia Pharmacovigilance market, 2014 - 2026 (USD Million)
目次
Product Code: 978-1-68038-327-0

The global pharmacovigilance market size is expected to reach USD 11.64 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 13.3% during the forecast period. Increasing incidence of Adverse Drug Reactions (ADR) is the key growth driver. The U.S. Food and Drug Administration (FDA) received approximately 253,017 serious adverse events and 44,693 deaths associated with ADRs in 2015. This shows the potential demand for implementing safety and Pharmacovigilance (PV) services.

According to the World Health Organization's (WHO) report on pharmaceuticals consumption, medicines to treat chronic diseases accounted for a larger proportion of the total volume of drug consumption in non-hospital set ups. Owing to this, there has been a significant rise in the number of medicines made available to healthcare consumers. Rising demand for drugs has significantly heightened the need for the development of novel therapeutics via extensive clinical trials, which is expected to serve this market with lucrative opportunities.

Major pharmaceutical companies are involved in extensive R&D initiatives for development of innovative therapeutic molecules. This has resulted in increased drug development activities. Manufacturers are now focusing on remodeling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for pharmacovigilance services during the forecast period.

Moreover, leading pharma companies in developed countries are focusing on outsourcing PV service in an attempt to reduce cost and to minimize operational expenses. This is anticipated to serve as an opportunity for contact research organizations in developing regions to gain more revenue share.

The companies operating in the pharmacovigilance market are undertaking strategic initiatives such as collaborations with the PV service providers to gain access to medical information and to manage PV workflows. For instance, In April 2017, Accenture entered in a collaborative agreement with BioCelebrate to develop a platform for aggregating and analyzing clinical information for improved drug developing efficiency, thus enhancing its R&D capabilities. These factors are anticipated to fuel the market growth.

Further key findings from the study suggest:

Phase IV held a dominant market share owing to the extensive post marketing surveillance of pharmaceuticals and increasing number of ADR incidences in the market

Phase III is anticipated to witness lucrative CAGR owing to increasing focus of pharmaceutical manufacturers on therapeutic development and safety monitoring

In service provider segment, contract outsourcing held a significant market share, owing to shift in focus of pharmaceutical companies to outsourcing services to reduce operational cost

Based on type of service, spontaneous reporting held the largest market share owing to its wide application in pharmacovigilance and benefits such as easy simulation of data sets for better drug comparison

Research organizations segment is anticipated to exhibit lucrative CAGR over the forecast period owing to increasing R&D for the development of novel biologics and medical devices

Asia Pacific pharmacovigilance market is anticipated to showcase lucrative CAGR in the forthcoming years

Industry participants are focusing on increasing R&D activities to develop better pharmacovigilance services.

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary Research:
    • 1.3.5 Details of Primary Research
      • 1.3.5.1 Data for primary interviews in North america
      • 1.3.5.2 Data for primary interviews in Europe
      • 1.3.5.3 Data for primary interviews in Asia Pacific
      • 1.3.5.4 Data for primary interviews in Middle East and Africa
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 Report Objectives

Chapter 2 Executive Summary

  • 2.1 Market Outlook
    • 2.1.1 Pharmacovigilance market Outlook, 2014 - 2026 (USD Million)
  • 2.2 Segment Outlook
  • 2.3 Competitive Outlook
  • 2.4 Pharmacovigilance Market Summary, 2018

Chapter 3 Pharmacovigilance Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market analysis
    • 3.1.2 Ancillary market Analysis
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Technology Timeline Overview
    • 3.3.1 Technology Timeline Pharmacovigilance changing technology & adoption
  • 3.4 Regulatory Framework
    • 3.4.1 List of regulatory bodies
  • 3.5 Pharmacovigilance Market Dynamics
    • 3.5.1 Market driver analysis
      • 3.5.1.1 Growing drug consumption and drug development rates
      • 3.5.1.2 Increasing incidence of ADR and drug toxicity
      • 3.5.1.3 Increasing trend of outsourcing pharmacovigilance services
    • 3.5.2 Market restraint analysis
      • 3.5.2.1 Lack of skilled labor
  • 3.6 Pharmacovigilance Market Analysis Tools: Porters
    • 3.6.1 Supplier Power
    • 3.6.2 Buyer Power
    • 3.6.3 Threat Of Substitutes
    • 3.6.4 Threat Of New Entrants
    • 3.6.5 Competitive Rivalary
  • 3.7 PESTEL Analysis
    • 3.7.1 Political Landscape
    • 3.7.2 economic Landscape
    • 3.7.3 technology Landscape
    • 3.7.4 technology Landscape
    • 3.7.5 social Landscape
  • 3.8 Major Deals & Strategic Alliances Analysis
    • 3.8.1 Mergers & Acquisitions
    • 3.8.2 product launch
    • 3.8.3 Expansion
    • 3.8.4 Partnership & Collaborations
    • 3.8.5 Market Entry Strategies

Chapter 4 Pharmacovigilance Market: Competitive Analysis

  • 4.1 Market Participation Categorization
  • 4.2 Public Companies
    • 4.2.1 Company market position analysis
    • 4.2.2 Competitive Dashboard Analysis
      • 4.2.2.1 Market Differentiators
    • 4.2.3 Company Market Share
    • 4.2.4 Competitive Dashboard Analysis
  • 4.3 Private Companies
    • 4.3.1 List of key emerging companies

Chapter 5 Pharmacovigilance Market: Product Estimates & Trend Analysis

  • 5.1 Product Market Share Analysis, 2018 & 2026
  • 5.2 Product Dashboard
    • 5.2.1 Preclinical
      • 5.2.1.1 Preclinical market estimates and forecasts, 2014 - 2026 (USD Million)
    • 5.2.2 Phase I
      • 5.2.2.1 Phase I market estimates and forecasts, 2014 - 2026 (USD Million)
    • 5.2.3 Phase II
      • 5.2.3.1 Phase II market estimates and forecasts, 2014 - 2026 (USD Million)
    • 5.2.4 Phase III
      • 5.2.4.1 Phase III market estimates and forecasts, 2014 - 2026 (USD Million)
    • 5.2.5 Phase IV
      • 5.2.5.1 Phase IV market estimates and forecasts, 2014 - 2026 (USD Million)

Chapter 6 Pharmacovigilance Market: Service provider Estimates & Trend Analysis

  • 6.1 Service provider Market Share Analysis, 2018 & 2026
  • 6.2 Service Provider Dashboard
  • 6.3 In house
    • 6.3.1 In house market estimates and forecasts, 2014 - 2026 (USD Million)
  • 6.4 Contract outsourcing
    • 6.4.1 Contract outsourcing market estimates and forecasts, 2014 - 2026 (USD Million)

Chapter 7 Pharmacovigilance Market: Type Estimates & Trend Analysis

  • 7.1 Type Market Share Analysis, 2018 & 2026
  • 7.2 Type Dashboard
  • 7.3 Spontaneous Reporting
    • 7.3.1 Spontaneous Reporting market estimates and forecasts, 2014 - 2026 (USD Million)
  • 7.4 Intensified ADR Reporting
    • 7.4.1 Intensified ADR Reporting market estimates and forecasts, 2014 - 2026 (USD Million)
  • 7.5 Targeted spontaneous reporting
    • 7.5.1 Targeted spontaneous reporting market estimates and forecasts, 2014 - 2026 (USD Million)
  • 7.6 Cohort Event Monitoring (CEM)
    • 7.6.1 Cohort Event Monitoring (CEM) market estimates and forecasts, 2014 - 2026 (USD Million)
  • 7.7 HER Mining
    • 7.7.1 HER Mining market estimates and forecasts, 2014 - 2026 (USD Million)

Chapter 8 Pharmacovigilance Market: End Use Estimates & Trend Analysis

  • 8.1 End Use Market Share Analysis, 2018 & 2026
  • 8.2 End Use Dashboard
  • 8.3 Hospitals
    • 8.3.1 Hospitals market estimates and forecasts, 2014 - 2026 (USD Million)
  • 8.4 Research organizations
    • 8.4.1 Research organizations market estimates and forecasts, 2014 - 2026 (USD Million)
  • 8.5 Industrial
    • 8.5.1 Industrial market estimates and forecasts, 2014 - 2026 (USD Million)

Chapter 9 Pharmacovigilance Market: Regional Estimates & Trend Analysis, By, Product, Service Providers, Type, And End Use

  • 9.1 Regional Market Snapshot
  • 9.2 Market Share Analysis by Country, 2018
    • 9.2.1 North America
    • 9.2.2 Europe
    • 9.2.3 Asia Pacific
    • 9.2.4 Latin America
    • 9.2.5 MEA
  • 9.3 North America
    • 9.3.1 North America Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.3.2 U.S.
      • 9.3.2.1 U.S. Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.3.3 Canada
      • 9.3.3.1 Canada Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
  • 9.4 Europe
    • 9.4.1 Europe Pharmacovigilance MARKET estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.4.2 U.K.
      • 9.4.2.1 U.K. Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.4.3 Germany
      • 9.4.3.1 Germany Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.4.4 France
      • 9.4.4.1 France Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.4.5 Italy
      • 9.4.5.1 Italy Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.4.6 Russia
      • 9.4.6.1 Russia Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
  • 9.5 Asia Pacific
    • 9.5.1 Asia Pacific Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.5.2 Japan
      • 9.5.2.1 Japan Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.5.3 China
      • 9.5.3.1 China Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.5.4 India
      • 9.5.4.1 India Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
  • 9.6 Latin America
    • 9.6.1 Latin America Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.6.2 Mexico
      • 9.6.2.1 Mexico Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.6.3 Brazil
      • 9.6.3.1 Brazil Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
  • 9.7 MEA
    • 9.7.1 MEA Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.7.2 South Africa
      • 9.7.2.1 South Africa Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)
    • 9.7.3 Saudi Arabia
      • 9.7.3.1 Saudi Arabia Pharmacovigilance market estimates and forecasts, 2014 - 2026 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Accenture
    • 10.1.1 Company overview
    • 10.1.2 Financial performance
    • 10.1.3 Product benchmarking
    • 10.1.4 Strategic initiatives
  • 10.2 Clinquest Group B.V.
    • 10.2.1 Company overview
    • 10.2.2 Product benchmarking
    • 10.2.3 Strategic initiatives
  • 10.3 Cognizant
    • 10.3.1 Company overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product benchmarking
    • 10.3.4 Strategic initiatives
  • 10.4 Laboratory Corporation of America Holdings
    • 10.4.1 Company overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product benchmarking
    • 10.4.4 Strategic initiatives
  • 10.5 IBM Corporation
    • 10.5.1 Company overview
    • 10.5.2 Product benchmarking
    • 10.5.3 Strategic initiatives
  • 10.6 ArisGlobal
    • 10.6.1 Company overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product benchmarking
    • 10.6.4 Strategic initiatives
  • 10.7 ICON Plc
    • 10.7.1 Company overview
    • 10.7.2 Product benchmarking
  • 10.8 Capgemini
    • 10.8.1 Company overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product benchmarking
    • 10.8.4 Strategic initiatives
  • 10.9 iMEDGlobal
    • 10.9.1 Company overview
    • 10.9.2 Financial performance
    • 10.9.3 Product benchmarking
    • 10.9.4 Strategic initiatives
  • 10.10 ITClinical
    • 10.10.1 Company overview
    • 10.10.2 Financial performance
    • 10.10.3 Product benchmarking
    • 10.10.4 Strategic initiatives
  • 10.11 Foresight Group International AG
    • 10.11.1 Company overview
    • 10.11.2 Financial performance
    • 10.11.3 Product benchmarking
    • 10.11.4 Strategic initiatives
  • 10.12 TAKE Solutions
    • 10.12.1 Company overview
    • 10.12.2 Financial performance
    • 10.12.3 Product benchmarking
    • 10.12.4 Strategic initiatives
  • 10.13 PAREXEL International Corporation
    • 10.13.1 Company overview
    • 10.13.2 Financial performance
    • 10.13.3 Product benchmarking
    • 10.13.4 Strategic initiatives
  • 10.14 BioClinica, Inc.
    • 10.14.1 Company overview
    • 10.14.2 Financial performance
    • 10.14.3 Product benchmarking
    • 10.14.4 Strategic initiatives
  • 10.15 Wipro Limited
    • 10.15.1 Company overview
    • 10.15.2 Financial performance
    • 10.15.3 Product benchmarking
    • 10.15.4 Strategic initiatives
  • 10.16 UNITED BIOSOURCE CORPORATION
    • 10.16.1 Company overview
    • 10.16.2 Financial performance
    • 10.16.3 Product benchmarking
    • 10.16.4 Strategic initiatives
Back to Top